Holen Sie sich die Stockscreener-App
6.2411
0.08%
-0.0011
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt NEO?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$6.24
Offen:
$6.27
24-Stunden-Volumen:
479.99K
Relative Volume:
0.23
Marktkapitalisierung:
$806.07M
Einnahmen:
$628.25M
Nettoeinkommen (Verlust:
$-78.55M
KGV:
-10.07
EPS:
-0.62
Netto-Cashflow:
$-29.73M
1W Leistung:
+2.55%
1M Leistung:
-0.08%
6M Leistung:
-50.98%
1J Leistung:
-62.78%
1-Tages-Spanne:
$6.18
$6.325
1-Wochen-Bereich:
$6.05
$6.35
52-Wochen-Spanne:
$4.72
$19.11
Neogenomics Inc Stock (NEO) Company Profile
Firmenname
Neogenomics Inc
Sektor
Branche
Telefon
(239) 768-0600
Adresse
9490 NEOGENOMICS WAY, FORT MYERS, FL
Vergleichen Sie NEO mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NEO
Neogenomics Inc
|
6.24 | 802.20M | 628.25M | -78.55M | -29.73M | -0.62 |
|
TMO
Thermo Fisher Scientific Inc
|
497.99 | 184.66B | 43.21B | 6.58B | 6.17B | 17.29 |
|
DHR
Danaher Corp
|
212.32 | 151.04B | 24.01B | 3.41B | 4.86B | 4.70 |
|
IDXX
Idexx Laboratories Inc
|
635.94 | 52.07B | 4.04B | 985.66M | 774.34M | 12.01 |
|
A
Agilent Technologies Inc
|
119.83 | 33.86B | 6.63B | 1.17B | 1.19B | 4.05 |
|
IQV
Iqvia Holdings Inc
|
192.99 | 32.49B | 15.70B | 1.24B | 2.01B | 6.91 |
Neogenomics Inc Stock (NEO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-30 | Herabstufung | BTIG Research | Buy → Neutral |
| 2025-07-29 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2025-05-15 | Eingeleitet | Guggenheim | Neutral |
| 2025-04-30 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2025-01-13 | Herabstufung | The Benchmark Company | Buy → Hold |
| 2024-12-10 | Eingeleitet | Jefferies | Buy |
| 2024-05-01 | Fortgesetzt | Craig Hallum | Buy |
| 2023-12-29 | Bestätigt | BTIG Research | Buy |
| 2023-08-21 | Hochstufung | Stephens | Equal-Weight → Overweight |
| 2023-05-16 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2023-05-09 | Hochstufung | BTIG Research | Neutral → Buy |
| 2023-02-24 | Hochstufung | The Benchmark Company | Hold → Buy |
| 2023-02-01 | Hochstufung | Needham | Hold → Buy |
| 2022-08-26 | Herabstufung | The Benchmark Company | Buy → Hold |
| 2022-08-22 | Herabstufung | Needham | Buy → Hold |
| 2022-06-03 | Eingeleitet | Piper Sandler | Overweight |
| 2022-03-29 | Herabstufung | BofA Securities | Buy → Neutral |
| 2022-03-29 | Herabstufung | Stephens | Overweight → Equal-Weight |
| 2022-01-18 | Fortgesetzt | Stephens | Overweight |
| 2021-12-16 | Eingeleitet | Cowen | Outperform |
| 2021-11-05 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-10-14 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2021-06-03 | Eingeleitet | Goldman | Buy |
| 2021-02-25 | Fortgesetzt | Needham | Buy |
| 2021-02-25 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2021-01-28 | Eingeleitet | Truist | Buy |
| 2020-12-11 | Fortgesetzt | BTIG Research | Buy |
| 2020-10-28 | Bestätigt | Needham | Buy |
| 2020-09-09 | Eingeleitet | Morgan Stanley | Overweight |
| 2020-08-28 | Eingeleitet | Guggenheim | Buy |
| 2020-07-29 | Bestätigt | Needham | Buy |
| 2020-06-25 | Eingeleitet | BofA/Merrill | Buy |
| 2020-04-21 | Fortgesetzt | Stephens | Overweight |
| 2020-03-02 | Fortgesetzt | Craig Hallum | Buy |
| 2020-02-28 | Hochstufung | First Analysis Sec | Outperform → Strong Buy |
| 2020-01-23 | Herabstufung | First Analysis Sec | Strong Buy → Outperform |
| 2019-10-30 | Bestätigt | Needham | Buy |
| 2019-05-01 | Bestätigt | Needham | Buy |
| 2019-03-29 | Bestätigt | Needham | Buy |
| 2019-01-03 | Eingeleitet | Needham | Buy |
| 2018-10-24 | Hochstufung | First Analysis Sec | Outperform → Strong Buy |
| 2018-08-21 | Eingeleitet | Leerink Partners | Outperform |
| 2018-05-02 | Herabstufung | First Analysis Sec | Overweight → Equal-Weight |
| 2017-09-11 | Herabstufung | BTIG Research | Buy → Neutral |
| 2017-08-24 | Eingeleitet | Gabelli & Co | Buy |
| 2016-12-15 | Eingeleitet | Cantor Fitzgerald | Overweight |
Alle ansehen
Neogenomics Inc Aktie (NEO) Neueste Nachrichten
Wyckoff Accumulation Phase Possible in NeoGenomics Inc.July 2025 Sector Moves & Low Risk Investment Opportunities - beatles.ru
NeoGenomics Reports Q2 Revenue of $181.3mln, Down from Estimates, Net Loss of $45.1mln. - AInvest
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NeoGenomics, Inc. - FinancialContent
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NeoGenomics - Bluefield Daily Telegraph
Smart tools for monitoring NeoGenomics Inc.’s price action - Newser
Pomerantz LLP investigates NeoGenomics for potential securities fraud. - AInvest
Tick level data insight on NeoGenomics Inc. volatilityWeekly Trade Summary & Growth-Oriented Investment Plans - Newser
Published on: 2025-08-16 04:12:30 - Newser
Published on: 2025-08-16 03:32:01 - Newser
NeoGenomics Inc.’s volatility index tracking explainedGlobal Markets & Real-Time Stock Entry Alerts - Newser
NeoGenomics Inc. stock momentum explainedTrade Ideas & AI Optimized Trading Strategy Guides - Newser
Best data tools to analyze NeoGenomics Inc. stockWeekly Trading Summary & Safe Entry Momentum Stock Tips - Newser
What makes NeoGenomics Inc. stock price move sharplyJuly 2025 Drop Watch & High Return Trade Guides - thegnnews.com
Analyzing NeoGenomics Inc. with multi timeframe chartsSell Signal & Real-Time Volume Trigger Notifications - Newser
Published on: 2025-08-15 15:19:39 - sundaytimes.kr
NeoGenomics Inc. Shows Early Signs of Technical StrengthQuarterly Trade Report & High Conviction Buy Zone Picks - classian.co.kr
Published on: 2025-08-15 08:46:44 - sundaytimes.kr
Real time alert setup for NeoGenomics Inc. performanceJuly 2025 Closing Moves & Weekly High Return Forecasts - Newser
NeoGenomics, Progyny, Repligen, Revvity, and Waters Corporation Shares Are Soaring, What You Need To Know - Yahoo Finance
NeoGenomics reports Q2 revenue of $181.3mln, misses estimates. - AInvest
NeoGenomics Earnings Outlook: Analysts Expect $-0.01 EPS, Guidance Key to Market Reaction - AInvest
AMN Healthcare Services, NeoGenomics, Acadia Healthcare, BrightSpring Health Services, and Repligen Shares Are Soaring, What You Need To Know - TradingView
NEO Q2 Deep Dive: Guidance Reset Amid Pharma Weakness, Delayed Product Launches - Yahoo Finance
NeoGenomics’s Q2 Earnings Call: Our Top 5 Analyst Questions - Yahoo Finance
NeoGenomics Misses Q2 Revenue Estimates, Decreases FY Guidance Amid Pharma Services Challenges and Product Launch Delays. - AInvest
Can NeoGenomics Inc. sustain its profitabilityCapital Rotation Trade Suggestions - thegnnews.com
NeoGenomics Board Member Resigns Amid Valuation Concerns - AInvest
NeoGenomics Board Member Elizabeth Floegel Resigns - TipRanks
Why NeoGenomics Inc. stock attracts strong analyst attentionBuy Low Sell High Stock Watch Strategy in Focus - metal.it
Is NeoGenomics (NEO) a Short-Term Bargain or a High-Risk Speculation? - AInvest
Why NeoGenomics (NEO) Stock Is Trading Up Today - Yahoo Finance
NEOGENOMICS Executives Make Significant Stock Purchases - TradingView
NeoGenomics (NEO) Targets Opportunity at $5 billion Liquid Biopsy Market - Insider Monkey
Envestnet Asset Management Inc. Reduces Stock Position in NeoGenomics, Inc. (NASDAQ:NEO) - Defense World
What are the latest earnings results for NeoGenomics Inc.Stay informed with expert market forecasts - Jammu Links News
Is NeoGenomics Inc. a good long term investmentMaximize gains with professional stock picks - Jammu Links News
What institutional investors are buying NeoGenomics Inc. stockAchieve consistent high returns with low risk - Jammu Links News
Is NeoGenomics Inc. a growth stock or a value stockInvest confidently with data-driven strategies - Jammu Links News
Should I hold or sell NeoGenomics Inc. stock in 2025Fastest-growing stock picks - Jammu Links News
NeoGenomics Inc. Stock Analysis and ForecastBuild wealth steadily with proven stock picks - Jammu Links News
How strong is NeoGenomics Inc. company’s balance sheetAchieve rapid wealth accumulation with smart picks - Jammu Links News
What is NeoGenomics Inc. company’s growth strategyGet timely advice on market trends - Jammu Links News
How volatile is NeoGenomics Inc. stock compared to the marketGet timely alerts on market opportunities - Jammu Links News
What drives NeoGenomics Inc. stock priceUnlock daily market insights for better decisions - Jammu Links News
What is the dividend policy of NeoGenomics Inc. stockBreakneck growth rates - Jammu Links News
How many analysts rate NeoGenomics Inc. as a “Buy”Free Popular Stock Recommendations - Jammu Links News
Does NeoGenomics Inc. stock perform well during market downturnsMaximize your returns with smart trade entries - Jammu Links News
What catalysts could drive NeoGenomics Inc. stock higher in 2025High-octane financial growth - Jammu Links News
Is NeoGenomics Inc. stock overvalued or undervaluedExplosive trading opportunities - Jammu Links News
What is the risk reward ratio of investing in NeoGenomics Inc. stockMaximize gains with data-driven stock picks - Jammu Links News
Finanzdaten der Neogenomics Inc-Aktie (NEO)
Umsatz
Nettogewinn
Free Cashflow
ENV
Neogenomics Inc-Aktie (NEO) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Zook Anthony P. | Chief Executive Officer |
Aug 06 '25 |
Buy |
5.58 |
17,900 |
99,954 |
38,066 |
| Williams Felicia | Director |
Jun 01 '25 |
Option Exercise |
0.00 |
7,160 |
0 |
7,160 |
| KANOVSKY STEPHEN M | Director |
Jun 01 '25 |
Option Exercise |
0.00 |
12,254 |
0 |
52,344 |
| Kelly Michael Aaron | Director |
Jun 01 '25 |
Option Exercise |
0.00 |
12,254 |
0 |
44,009 |
| TETRAULT LYNN A. | Director |
Jun 01 '25 |
Option Exercise |
0.00 |
12,254 |
0 |
73,652 |
| Floegel Elizabeth | Director |
Jun 01 '25 |
Option Exercise |
0.00 |
12,254 |
0 |
23,590 |
| Gunn Neil | Director |
Jun 01 '25 |
Option Exercise |
0.00 |
12,254 |
0 |
28,100 |
| Zook Anthony P. | Chief Executive Officer |
Jun 01 '25 |
Option Exercise |
0.00 |
12,254 |
0 |
23,590 |
| Perez David Brian | Director |
Jun 01 '25 |
Option Exercise |
0.00 |
12,254 |
0 |
33,890 |
| Kelly Michael Aaron | Director |
May 27 '25 |
Buy |
7.60 |
5,000 |
38,000 |
5,000 |
2.77%
0.15%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):